Obseva (OBSV) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Obseva (NASDAQ:OBSV) from a hold rating to a buy rating in a research report sent to investors on Saturday. They currently have $18.00 price objective on the stock.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
A number of other brokerages have also weighed in on OBSV. Wedbush set a $34.00 target price on Obseva and gave the company a buy rating in a research report on Wednesday, October 3rd. TheStreet raised Obseva from a d+ rating to a c- rating in a research report on Thursday, October 11th. HC Wainwright set a $44.00 target price on Obseva and gave the company a buy rating in a research report on Monday, October 15th. Finally, JPMorgan Chase & Co. started coverage on Obseva in a research report on Thursday, September 13th. They set an overweight rating and a $29.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $29.29.
Obseva (NASDAQ:OBSV) last issued its earnings results on Thursday, November 8th. The company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.04. Research analysts anticipate that Obseva will post -1.86 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in OBSV. US Bancorp DE bought a new position in shares of Obseva in the 2nd quarter worth $197,000. Tiverton Asset Management LLC bought a new position in shares of Obseva in the 2nd quarter worth $224,000. FMR LLC bought a new position in shares of Obseva in the 2nd quarter worth $27,254,000. Vivo Capital LLC bought a new position in shares of Obseva in the 2nd quarter worth $14,005,000. Finally, DAFNA Capital Management LLC raised its position in shares of Obseva by 857.7% in the 2nd quarter. DAFNA Capital Management LLC now owns 64,977 shares of the company’s stock worth $984,000 after acquiring an additional 58,192 shares in the last quarter. 72.19% of the stock is owned by hedge funds and other institutional investors.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.